DAY ONE – Plenary - Monday 21st May 2012

last modified: 22 May '12

Please enable javascript to see more information on speakers

9am

Chairman’s opening remarks

Prof. Chris Mason

Prof. Chris Mason MBBS, PhD, FSB, FRCSI, FRCS Stem Cell & Regenerative Medicine Bioprocessing Unit Advanced Centre for Biochemical Engineering University College London Mason is internationally recognized to be at the forefront of the emerging...

more..

› Prof. Chris Mason, Chair of Regenerative Medicine Bioprocessing, UCL

DRIVING CELL THERAPIES THROUGH THE TECHNOLOGY AND INNOVATION CENTRE

9.10am

Keynote address: a national take on innovation: learning from past mistakes

Rt Hon David Willetts MP

David is the Minister for Universities and Science, and has been the Member of Parliament for Havant since 1992. David has worked at HM Treasury, the Number 10 Policy Unit, the Centre for Policy Studies and served as Paymaster General in the last...

more..

Specific bullets to be confirmed

› Rt Hon David Willetts MP, Minister for Universities & Science, UK Government

TRANSLATING RESEARCH AND ACCELERATING TO MARKET

9.40am

The vision for the Cell Therapy Catapult

Keith Thompson

Keith Thompson was appointed CEO of the Cell Therapy Catapult on 1st May 2012 to establish and lead the Centre. For the last eight years he was the Director of the Scottish National Blood Transfusion Service where he was responsible for providing...

more..

Establishing the Catapult in London
Experience in bringing cell therapies into clinical use
How will the Catapult work?
How will it impact the Cell Therapy industry?

› Keith Thompson, Chief Executive Officer, Catapult Centre in Cell Therapy

10.20am

Panel discussion: global translation centres collaborating to advance stem cell therapies

Dr. Michael May

Michael May is currently the Chief Executive Officer of the Centre for Commercialization of Regenerative Medicine (CCRM) a Canadian, federally incorporated, not-for-profit organization dedicated to supporting the development of foundational...

more..

Todd McAllister

Dr. McAllister has a Ph.D. in BioMedical Engineering from the University of California, San Diego. He is the co-founder and CEO of Cytograft Tissue Engineering, Inc. Dr. McAllister has been an early proponent of tissue engineered self-assembly...

more..

Zahid Latif

Zahid qualified as a pharmacist and after a stint in hospital pharmacy, went on to complete a PhD in pharmaceutical chemistry. He then spent 11 years in R&D working with SME's such as MNL & Integrin and multinationals such as Wyeth. He joined the...

more..

How do Translation Centres work individually on a national level to advance cell therapies?
How can Translation Centres interact and collaborate internationally?
Driving forward a therapy that is economically and clinically a good choice

11am

Speed Networking

11.30am

Morning Refreshments

12pm

A roadmap for advancing pre-clinical research through to the clinic

Frank Lauter

Dr. Frank-Roman Lauter is Head of Business Development (BD) at the Berlin-Brandenburg Center for Regenerative Therapies (BCRT) & Spokesman of the German-Californian RegMed Initiative. Trained as a molecular biologist at the Max-Planck-Institute in...

more..

Taking the right steps to “cross the valley of death”
How can the most promising pre-clinical research be efficiently taken to the clinical stage?
What are the needs of successfully advancing cell therapies?
How can this be done quickly and cost effectively?

› Frank Lauter, Head of Business Development, Berlin-Brandenburg Centre for Regenerative Therapies

12.25pm

Identifying what should be demonstrated in successful clinical trials

Gil Van Bokkelen

Dr. Gil Van Bokkelen is the Chairman and CEO of Athersys, Inc. (NASDAQ: ATHX), a biopharmaceutical company based in Cleveland, Ohio that was established in 1995. He has served as Chairman of the Board of Directors at Athersys since August, 2000, and ...

more..

What data needs to be generated in pivotal stem cell therapy trials?
What are the practical problems to overcome?
What is in place to ensure failure at the late-stage clinical trial is avoided?
How are the clinical end points established to depict significant clinical added value?

› Gil Van Bokkelen, Chairman & CEO, Athersys

12.50pm

Panel discussion: where do large pharma see themselves in the burgeoning stem cell industry?

Joe Amaral

Dr. Joseph Amaral is a proven strategic leader with significant achievements in revitalizing a major regional healthcare institution, exploring and developing new medical technologies, and educating international communities in new surgical...

more..

Mr Matthias Steger

Dr Steger is Global Head Research & Technology Partnering at Roche, and in this role is also responsible for the company’s collaborations in the area of stem cell technologies and therapeutics. Dr Steger is co-chair of the International Society for...

more..

Dr Ruth McKernan

Ruth McKernan is Senior Vice President Pfizer and Chief Scientific Officer of the corporation’s Neusentis research Unit. Neusentis is a consolidation of Pfizer’s Pain & Sensory Disorders, Regenerative Medicine & Epigenetics research activities. ...

more..

Big pharma perspective on accelerating therapies through to bedside
Where is big pharma looking to position itself in the next generation of stem cell therapies?
How can pharma act to drive therapies to the global market?
What do pharma need to see as they increase their presence in the stem cell space?